Skip to main content

Table 1 Patients with post-SARS-CoV-2 vaccination VST reported in the literature

From: Post-SARS-CoV-2 vaccination venous sinus thrombosis: a literature review of 308 cases

Age Sex Dose Company locSVT Latency (days) Therapy Outcome References
53 f 1st A Cavernous 11 Intubation, platelets Death [9]
55 m 1st A Cavernous 8 Steroids, argatroban Death [9]
30* f 1st A Transverse, sigmoid 7 Argatroban, IVIG PR [10]
30 f 1st A nr 9 Tinzaparin, rivaroxaban PR [11]
27* m 1st A nr 2 Dabigatran, IVIG Death [12]
54* m nr A nr 14 Danaparoid, IVIG, DOAC Alive [13]
49 m 1st P Transverse, sigmoid 16 Clexane, apixaban Alive [14]
69 f 1st A Sigmoid, SSS 11 nr Death [5]
32 m 1st A SSS 9 None Death [14]
25* m 1st A SSS 6 Heparin, platelets, IVIG, steroids Death [14]
22 f 1st A SSS, transverse 4 Enoxaparin, dabigatran PR [15]
46 f 1st A SSS, sigmoid, transverse 8 Danaparoid, dabigatran PR [15]
36 f 1st A SSS, straight 7 Enoxaparin, dabigatran CR [15]
50 m 1st A Transverse, sigmoid 7 Craniotomy Death [16]
61 f nr A nr 14 Enoxaparin Discharged [17]
40 m 1st A nr 14 Enoxaparin, apixaban Discharged [17]
50 m 1st A SSS, sigmoid 7 Enoxaparin, craniotomy Death [18]
42 f 1st A SSS, straight sigmoid 0 Enoxaparin, craniotomy Coma [18]
55 f 2nd P Straight, sigmoid 1 Enoxaparin Death [18]
32 f 1st A Straight, sigmoid 1 Fondaparinux, steroids Death [18]
35 f 1st A SSS, straight sigmoid 6 Enoxaparin, steroids, PE Coma [18]
51 f 1st A Straight, sigmoid 10 Ventriculostomy Death [18]
64 m 1st A SSS, straight, sigmoid 4 Enoxaparin CR [18]
40 f 1st A SSS, straight sigmoid 5 Fondaparinux PR [18]
49 f 1st A straight, sigmoid 11 Enoxaparin PR [18]
54 f 1st A SSS, Galen 2 Enoxaparin, steroids Death [18]
55 f 1st A Jugular 6 Fondaparinux craniotomy Death [18]
54 f nr A Labbe, Galen 12 Intubation Death [20]
39 f 1st A Sigmoid, transverse 6 Danaparoid dabigatran, IVIG CR [20]
24* f 1st A Cortical 8 Argatroban, steroids, IVIG CR [21]
32 f 1st A nr 11 nr Death [22]
29* m 1st A Sigmoid, transverse 9 IVIG, agratroban Recovery [23]
>40 nr nr J Transverse, sigmoid 6 nr ND [23]
18-39 nr nr J Transverse, sigmoid 9 nr Discharged [23]
18-39 nr nr J SSS, straight, 8 nr ND [23]
18-39 nr nr J Transverse, sigmoid 8 nr Discharged [23]
18-39 nr nr J Transverse, sigmoid 6 nr ND [23]
>40 nr nr J Transverse, straight 13 nr ND [23]
18-39 nr nr J SSS, straight, transverse 15 nr ND [23]
18-39 nr nr J Transverse, sigmoid 10 nr Discharged [23]
>40 nr nr J SSS, cortical 7 nr ND [23]
18-39 nr nr J Transverse, SSS, sigmoid 7 nr ND [23]
18-39 nr nr J Transverse, sigmoid 11 nr ND [23]
>40 nr nr J Transverse, sigmoid 6 nr Discharged [24]
51 m 1st C SSS, transverse 6 Heparin, warfarin PR [25]
40 f 1st J nr 5 Bivalirudin CR [26]
36 f 1st A SSS 14 Enoxaparin Death [27]
25 f 1st A Cortical 12 nr nr [28]
50* m 1st A Transverse, sigmoid 14 Desirudin PR [29]
30* f 1st A None 8 Tinzaparin PR [11]
ϴ46.7 (n = 45) 35f 1st (42) A (n = 37) nr nr nr nr [30]
   2nd (3) P (n = 8)      
32-81 (n = 213) 138 f
46 m
1st (except 2) P (n = 25)
M (n = 1)
A (n = 187)
nr 2-21d  nr Death (n = 46) [31]
  1. A: ChAdOx1-S, C: ChAdOx1-S from India, CR: complete recovery, DOAC: direct oral anticoagulant, locSVT: location of venous sinus thrombosis, ip: in preparation, IVIG: intravenous immunoglobulins, J: JNJ-78436735, M: mRNA-1273, ND: not discharged, nr: not reported, P: BNT126b2, PE: plasma exchange, PR: partial recovery at discharge or late follow-up (patient had not reached his pre-morbid condition), SSS: superior sagittal sinus, *: associated with immune thrombocytopenia